Company intelligence / Profile preview
PIF Partners
New York City, New York, United Statespartnersinflight.org ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
PIF Partners' lead program, 101-PGC-005 ('005), a Type IA prodrug of dexamethasone targeting CD206+ macrophages, has received FDA Rare Pediatric Disease Designation for sJIA flares and is currently in Phase 3 clinical trials in India for ARDS due to COVID-19. The compound aims to enhance efficacy and reduce toxicity compared to standard corticosteroids, with no suppression of the HPA system observed so far.
- Therapeutic areas
- PulmonologyImmunologyRheumatology
- Modalities
- Small moleculeProdrug therapy
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on PIF Partners.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PIF Partners.